News from naurex inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 22, 2015, 08:00 ET

Naurex to Present Clinical Data for NRX-1074 at 2015 American Society of Clinical Psychopharmacology Annual Meeting

 Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the brain and nervous system,...

May 12, 2015, 08:00 ET

Naurex to Present Preclinical and Clinical Data for NRX-1074 and Rapastinel at Upcoming Scientific Meetings

Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the brain and nervous system, today...

Mar 13, 2015, 13:54 ET

Naurex to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

 Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system...

Jan 27, 2015, 08:00 ET

Naurex's First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement in Depression Scores within 24 Hours in Phase 2 Study for Major Depressive Disorder

Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS),...

Dec 19, 2014, 11:07 ET

Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference

Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system, today...

Dec 10, 2014, 08:00 ET

Naurex's GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects and Excellent Tolerability in Phase 2b Study

 Naurex Inc. today announced that Phase 2b data presented at the Annual Meeting of the American College of Neuropsychopharmacology demonstrated...

Dec 03, 2014, 07:30 ET

Naurex Raises $80 Million in Series C Financing to Advance Novel NMDA Receptor Modulators in Depression and Other CNS Disorders

 Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system...

Nov 17, 2014, 09:00 ET

Data Presented at Society for Neuroscience Demonstrates that Naurex's GLYX-13 Enhances Synaptic Plasticity through NMDA Receptor Modulation

 Naurex Inc. today announced that data presented at the Society for Neuroscience conference demonstrate that the company's lead therapeutic...

May 15, 2014, 07:30 ET

Naurex to Present at UBS Global Healthcare Conference

 Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, PhD, will present at the UBS Global Healthcare...

May 06, 2014, 07:30 ET

Naurex Reports Positive Top-Line Phase 2b Results for Novel Antidepressant GLYX-13 and Advances NRX-1074 into Phase 2 Depression Study

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous...

Mar 03, 2014, 07:30 ET

FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13

 Naurex Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of...

Feb 27, 2014, 07:30 ET

Naurex to Present at Cowen and Co. 34th Annual Health Care Conference

Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, Ph.D., will present at the Cowen and Company 34th...

Jan 09, 2014, 17:09 ET

Naurex to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Naurex Inc. today announced that Norbert G. Riedel, Ph.D., long-term board member and newly-appointed president and chief executive officer of...

Jan 08, 2014, 08:00 ET

Naurex Names Dr. Norbert G. Riedel President and Chief Executive Officer

 Naurex Inc. today announced that Norbert G. Riedel, Ph.D., has been named president and chief executive officer effective January 1,...

Dec 12, 2013, 08:00 ET

Naurex Presents Data on Rapid-Acting Antidepressant GLYX-13 that Support Long-term Synaptic Plasticity as Its Mechanism of Action

 Naurex Inc. today announced the presentation of preclinical data at the 52nd Annual Meeting of the American College of Neuropsychopharmacology...

Jul 30, 2013, 07:30 ET

Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced...

Jun 04, 2013, 07:30 ET

Naurex Announces Initiation Of Phase I Trial For Second-Generation Novel Antidepressant Agent NRX-1074

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced...

Dec 17, 2012, 07:30 ET

Naurex Completes $38 Million Series B Financing

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the...

Dec 06, 2012, 07:30 ET

Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported...

Nov 07, 2011, 08:00 ET

Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's 2011 Top 10 Neuroscience Projects to Watch

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today...